title: Gardos pathway to sickle cell therapies?
abstract: In this issue of Blood, Ataga and colleagues report that treatment of sickle cell disease patients with senicapoc, a Gardos channel inhibitor, reduces the number of dehydrated cells, increases hemoglobin levels, and diminishes hemolysis.
authors.affiliation: Cincinnati Children's Hospital Medical Center, USA.
authors.forename: Clinton H
authors.initials: CH
authors.lastname: Joiner